2. Academic Validation
  3. Lenalidomide induces degradation of IKZF1 and IKZF3

Lenalidomide induces degradation of IKZF1 and IKZF3

  • Oncoimmunology. 2014 Jul 3;3(7):e941742. doi: 10.4161/21624011.2014.941742.
Jan Krönke 1,  Slater N Hurst 1,  Benjamin L Ebert 1
Affiliations

Affiliation

  • 1 Brigham and Women's Hospital ; Boston, MA USA.
PMID: 25610725 DOI: 10.4161/21624011.2014.941742
Abstract

Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).

Keywords

lenalidomide; pomalidomide; thalidomide; ubiquitin.

Figures
Products